Loading clinical trials...
Loading clinical trials...
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of HEC96719 in non-cirrhotic NASH patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sunshine Lake Pharma Co., Ltd.
NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more
NCT06819917 · Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and more
NCT06661655 · Metabolic Syndrome X, Fatty Liver, and more
NCT03151473 · Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
NCT06519448 · Non-alcoholic Steatohepatitis, Liver Diseases, and more
Peking University People's Hospital
Beijing, Beijing Municipality
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong
Affiliated Hospitol of Guangdong Medical University
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions